

Victor Manuel Vargas Blasco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5836931/publications.pdf>

Version: 2024-02-01

135
papers

12,267
citations

36303

51
h-index

25787

108
g-index

141
all docs

141
docs citations

141
times ranked

9034
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. <i>Gut</i> , 2022, 71, 1856-1866.	12.1	17
2	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ACH). <i>Liver International</i> , 2022, 42, 1109-1120.	3.9	20
3	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
4	Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. <i>Journal of Clinical Medicine</i> , 2022, 11, 2466.	2.4	3
5	Value of pilot studies in alcohol-associated hepatitis. <i>Liver International</i> , 2022, 42, 1697-1697.	3.9	0
6	Does Routine Abdominal Drain Tip Culture Anticipate Post-Operative Infection in Liver Transplantation?. <i>Surgical Infections</i> , 2021, 22, 222-226.	1.4	3
7	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
8	Frailty in outpatients with cirrhosis: A prospective observational study. <i>Liver International</i> , 2021, 41, 357-368.	3.9	12
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
10	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
11	Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 2250-2257.	0.4	14
12	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
13	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021, 27, 1382-1391.	2.4	4
14	A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. <i>JHEP Reports</i> , 2021, 3, 100291.	4.9	23
15	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	7.3	151
16	The <i>Candida albicans</i> exotoxin candidalysin promotes alcohol-associated liver disease. <i>Journal of Hepatology</i> , 2020, 72, 391-400.	3.7	119
17	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020, 72, 472-480.	3.7	130
18	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75

#	ARTICLE	IF	CITATIONS
19	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	4.4	77
20	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	4.1	39
21	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
22	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
23	Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102267.	3.3	12
24	326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY. <i>Gastroenterology</i> , 2020, 158, S-1268.	1.3	0
25	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1121-1129.	3.9	15
26	Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series. <i>Brain and Behavior</i> , 2020, 10, e01596.	2.2	9
27	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	7.3	74
28	Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. <i>Hepatology</i> , 2020, 71, 1106-1116.	7.3	22
29	Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2020, 52, e30.	0.9	5
30	Routine Bile Culture From Liver Donors as Screening of Donor-Transmitted Infections in Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1121-1126.	2.4	4
31	Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report. <i>World Journal of Hepatology</i> , 2020, 12, 1128-1135.	2.0	2
32	Patients with Compensated Cirrhosis Are Also at Risk of Falling. <i>Hepatology</i> , 2019, 69, 455-457.	7.3	1
33	246 Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. <i>Gastroenterology</i> , 2019, 156, S-1186.	1.3	2
34	Mo1468 Long Term Assessment of the Effects of Obeticholic Acid in Patients with Primary Biliary Cholangitis on Immune and Inflammatory Markers. <i>Gastroenterology</i> , 2019, 156, S-1317.	1.3	0
35	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
36	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 445-453.	8.1	116

#	ARTICLE	IF	CITATIONS
37	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
38	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
39	PTU-009...Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers. , 2019, , .		0
40	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
41	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	27.8	493
42	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
43	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 446-452.	0.4	65
44	Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018, 27, 1513-1520.	3.1	30
45	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	3.7	144
46	Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections. Results from the ICA "Global Study". <i>Digestive and Liver Disease</i> , 2018, 50, 23-24.	0.9	0
47	A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis. <i>Liver Transplantation</i> , 2018, 24, 1655-1664.	2.4	41
48	Mo1454 - Durable Response in the Markers of Cholestasis Through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2018, 154, S-1211-S-1212.	1.3	1
49	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 2513-2522.	4.7	32
50	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	3.7	152
51	High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. <i>Clinical Microbiology and Infection</i> , 2017, 23, 775.e1-775.e6.	6.0	11
52	Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017, 67, 940-949.	3.7	85
53	Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 535-538.	1.6	0
54	Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 981-991.	3.7	46

#	ARTICLE	IF	CITATIONS
55	Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. <i>American Journal of Transplantation</i> , 2016, 16, 679-687.	4.7	11
56	Sa1579 Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2016, 150, S1073-S1074.	1.3	1
57	Predictive model of mortality in patients with spontaneous bacterial peritonitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 629-637.	3.7	19
58	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550
59	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	27.0	817
60	Evaluation and treatment of the critically ill cirrhotic patient. <i>Gastroenterology</i> Y <i>Hepatology</i> (English Edition), 2016, 39, 607-626.	0.1	1
61	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 488-498.	7.3	27
62	Clinical laboratory standard capillary protein electrophoresis alerted of a low C3 state and lead to the identification of a Factor I deficiency due to a novel homozygous mutation. <i>Immunology Letters</i> , 2016, 174, 19-22.	2.5	7
63	Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese. <i>BBA Clinical</i> , 2016, 5, 54-65.	4.1	8
64	Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. <i>World Journal of Gastroenterology</i> , 2015, 21, 10475.	3.3	12
65	Doubtful Role of IL28B Polymorphism in Occult Hepatitis B Infection. <i>Intervirology</i> , 2015, 58, 160-165.	2.8	0
66	Morbidly "Healthy" Obese Are Not Metabolically Healthy but Less Metabolically Imbalanced Than Those with Type 2 Diabetes or Dyslipidemia. <i>Obesity Surgery</i> , 2015, 25, 1380-1391.	2.1	15
67	Etiology and mortality of spontaneous bacterial peritonitis in liver transplant recipients: A cohort study. <i>Liver Transplantation</i> , 2014, 20, 856-863.	2.4	5
68	Brain Magnetic Resonance Spectroscopy in Episodic Hepatic Encephalopathy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 272-277.	4.3	41
69	Soluble CD40 Ligand in Morbidly Obese Patients. <i>JAMA Surgery</i> , 2013, 148, 151.	4.3	16
70	T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. <i>Journal of Hepatology</i> , 2012, 56, 765-774.	3.7	58
71	Alterations in the Common Pathway of Coagulation During Weight Loss Induced by Gastric Bypass in Severely Obese Patients. <i>Obesity</i> , 2012, 20, 1048-1056.	3.0	21
72	Cognitive dysfunction in cirrhosis is associated with falls: A prospective study. <i>Hepatology</i> , 2012, 55, 1922-1930.	7.3	93

#	ARTICLE	IF	CITATIONS
73	Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. <i>Liver Transplantation</i> , 2012, 18, 201-205.	2.4	34
74	Only C-Reactive Protein, but not TNF- α or IL6, Reflects the Improvement in Inflammation after Bariatric Surgery. <i>Obesity Surgery</i> , 2012, 22, 131-139.	2.1	61
75	Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. <i>World Journal of Hepatology</i> , 2012, 4, 382.	2.0	58
76	Minimal Hepatic Encephalopathy Is Associated With Falls. <i>American Journal of Gastroenterology</i> , 2011, 106, 476-482.	0.4	180
77	Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?. <i>Annals of Hepatology</i> , 2011, 10, 180-187.	1.5	19
78	Hyperkalemic Distal Renal Tubular Acidosis Caused by Immunosuppressant Treatment with Tacrolimus in a Liver Transplant Patient: Case Report. <i>Transplantation Proceedings</i> , 2011, 43, 4016-4018.	0.6	15
79	Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. <i>Liver Transplantation</i> , 2011, 17, 38-46.	2.4	129
80	Biexponential Analysis of Diffusion-Tensor Imaging of the Brain in Patients with Cirrhosis before and after Liver Transplantation. <i>American Journal of Neuroradiology</i> , 2011, 32, 1510-1517.	2.4	30
81	A Long-Term Study of Changes in the Volume of Brain Ventricles and White Matter Lesions After Successful Liver Transplantation. <i>Transplantation</i> , 2010, 89, 589-594.	1.0	36
82	The Relationships Between IGF-1 and CRP, NO, Leptin, and Adiponectin During Weight Loss in the Morbidly Obese. <i>Obesity Surgery</i> , 2010, 20, 623-632.	2.1	57
83	Increased Expression and Activity of Hepatic Lipase in the Liver of Morbidly Obese Adult Patients in Relation to Lipid Content. <i>Obesity Surgery</i> , 2009, 19, 894-904.	2.1	36
84	Ghrelin and Apolipoprotein AIV Levels Show Opposite Trends to Leptin Levels During Weight Loss in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2009, 19, 1414-1423.	2.1	35
85	Lipoprotein Lipase Expression in Livers of Morbidly Obese Patients Could be Responsible for Liver Steatosis. <i>Obesity Surgery</i> , 2009, 19, 608-616.	2.1	54
86	Lipoprotein Lipase but Not Hormone-Sensitive Lipase Activities Achieve Normality After Surgically Induced Weight Loss in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2009, 19, 1150-1158.	2.1	23
87	Visceral leishmaniasis among liver transplant recipients: An overview. <i>Liver Transplantation</i> , 2008, 14, 1816-1819.	2.4	25
88	Liver Transplantation in HIV-HCV Coinfected Patients: A Case-Control Study. <i>Transplantation</i> , 2007, 83, 354-358.	1.0	31
89	Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2007, 47, 366-372.	3.7	76
90	[473] SEROLOGICAL AND MOLECULAR MARKERS OF HEPATITIS B VIRUS IN SPANISH BLOOD DONORS: EVIDENCE OF OCCULT HEPATITIS B. <i>Journal of Hepatology</i> , 2007, 46, S179-S180.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 818-824.	1.3	639
92	Molecular Tracing of the Global Hepatitis C Virus Epidemic Predicts Regional Patterns of Hepatocellular Carcinoma Mortality. <i>Gastroenterology</i> , 2006, 130, 703-714.	1.3	106
93	Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. <i>Haemophilia</i> , 2006, 12, 228-236.	2.1	10
94	Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. <i>Liver Transplantation</i> , 2006, 12, 95-104.	2.4	89
95	Pancreatic pseudocyst located in the liver. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 616-20.	0.3	14
96	Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2006, 11, 1061-1070.	1.0	23
97	Resection of hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Surgery</i> , 2005, 83, 758-761.	0.3	83
98	Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 1242-1251.	2.4	189
99	Combined treatment with pegylated interferon ($\hat{1}\pm$ -2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2005, 43, 53-59.	3.7	148
100	Psychosocial adjustment to orthotopic liver transplantation in 266 recipients. <i>Liver Transplantation</i> , 2004, 10, 228-234.	2.4	53
101	Trasplante hepatico en pacientes con infeccin por el VIH: una realidad en el ao 2004. <i>Enfermedades Infecciosas Y Microbiologa Clnica</i> , 2004, 22, 529-538.	0.5	7
102	T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. <i>Hepatology</i> , 2003, 38, 1026-1033.	7.3	60
103	Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. <i>Transplant International</i> , 2003, 16, 270-275.	1.6	7
104	Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. <i>Journal of Hepatology</i> , 2003, 38, 51-58.	3.7	212
105	Quality of life and cognitive function in hepatitis C at different stages of liver disease. <i>Journal of Hepatology</i> , 2003, 39, 231-238.	3.7	196
106	Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. <i>Transplant International</i> , 2003, 16, 270-5.	1.6	2
107	T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. <i>Hepatology</i> , 2003, 38, 1026-1033.	7.3	22
108	Outcome of cirrhotic patients with incidental hepatocellular carcinoma undergoing liver transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 299-300.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Daily norfloxacin is more effective than weekly rifloxacin in prevention of spontaneous bacterial peritonitis recurrence. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1356-1361.	2.3	58
110	Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 892-900.	2.4	33
111	The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. <i>Journal of Hepatology</i> , 2001, 35, 598-604.	3.7	233
112	Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis. <i>Lupus</i> , 2001, 10, 628-631.	1.6	25
113	Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. <i>Liver International</i> , 1999, 19, 177-182.	3.9	42
114	Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. <i>Transplantation Proceedings</i> , 1999, 31, 2464-2465.	0.6	28
115	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. <i>New England Journal of Medicine</i> , 1999, 341, 403-409.	27.0	1,519
116	OUTCOME OF HEPATITIS C VIRUS-ASSOCIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1999, 68, 1131-1134.	1.0	15
117	Cytomegalovirus Disease as a Risk Factor for Graft Loss and Death After Orthotopic Liver Transplantation. <i>Clinical Infectious Diseases</i> , 1998, 26, 865-870.	5.8	66
118	<i>Listeria monocytogenes</i> -associated acute hepatitis in a liver transplant recipient. <i>Liver</i> , 1998, 18, 213-215.	0.1	22
119	Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. <i>Transplant International</i> , 1997, 10, 462-465.	1.6	13
120	Relevance of positive lymphocytotoxic crossmatch and immunosuppressive regimens in the outcome of liver transplants. <i>Transplantation Proceedings</i> , 1997, 29, 461-462.	0.6	1
121	Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation. <i>Journal of Hepatology</i> , 1996, 24, 452-459.	3.7	41
122	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. <i>Hepatology</i> , 1995, 21, 674-679.	7.3	171
123	Long interval between HCV infection and development of hepatocellular carcinoma. <i>Liver</i> , 1995, 15, 159-163.	0.1	52
124	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. <i>Hepatology</i> , 1995, 21, 674-679.	7.3	10
125	Drug-Induced Lupus-Like Reaction and Captopril. <i>Annals of Pharmacotherapy</i> , 1993, 27, 1541-1542.	1.9	7
126	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. <i>New England Journal of Medicine</i> , 1991, 325, 829-835.	27.0	294

#	ARTICLE	IF	CITATIONS
127	Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. <i>Hepatology</i> , 1990, 12, 716-724.	7.3	587
128	A Multicenter, Randomized, Double-Blind Study Comparing a Daily Bedtime Administration of Famotidine and Ranitidine in Short-Term Treatment of Active Duodenal Ulcer. <i>Digestion</i> , 1989, 42, 79-85.	2.3	4
129	A multicentre, randomized, double-blind study comparing nocte famotidine or ranitidine for the treatment of active duodenal ulceration. <i>Alimentary Pharmacology and Therapeutics</i> , 1989, 3, 103-110.	3.7	7
130	Lupus anticoagulant and portal hypertension. <i>American Journal of Medicine</i> , 1988, 84, 566-568.	1.5	27
131	MATERNAL-FETAL TRANSMISSION OF HEPATITIS A ANTIBODY. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1980, 69, 533-533.	1.5	6
132	HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS MARKERS IN EUROPE. <i>Lancet, The</i> , 1979, 313, 721-722.	13.7	4
133	HAAb TITRES IN HEPATITIS A. <i>Lancet, The</i> , 1979, 313, 610-611.	13.7	0
134	Early pleural effusion in histiocytosis X. <i>Archives of Internal Medicine</i> , 1979, 139, 934-936.	3.8	1
135	ANTI-HEPATITIS-A ANTIBODY IN SPAIN. <i>Lancet, The</i> , 1978, 312, 583.	13.7	7